Who
Christopher Peetz
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Mirum Pharmaceuticals; Director, Arcutis Biotherapeutics; Director, Alpine Immune Sciences; Chief Financial Officer, Tobira Therapeutics.
In numbers
- Trades disclosed
- 165
- Buys
- 5
- Sells
- 21
- Bought
- $314K
- Sold
- $42.1M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 6 May 2015
- Last trade
- 6 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 6 Oct 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $102K5,305 at $19.19 | filing |
| 6 Oct 2026filed 6 Oct 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $109K6,892 at $15.87 | filing |
| 6 Oct 2026filed 6 Oct 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,305 at $0.00 | filing |
| 6 Oct 2026filed 6 Oct 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,892 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $88K30,000 at $2.94 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $815K8,312 at $98.08 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.1M21,688 at $98.91 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —30,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —30,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $88K30,000 at $2.94 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $815K8,312 at $98.08 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.1M21,688 at $98.91 | filing |
| 10 Aug 2026filed 11 Aug 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $59K20,000 at $2.94 | filing |
| 10 Aug 2026filed 11 Aug 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M11,683 at $98.51 | filing |
| 10 Aug 2026filed 11 Aug 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $597K6,017 at $99.25 | filing |
| 10 Aug 2026filed 11 Aug 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 10 Aug 2026filed 11 Aug 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $230K2,300 at $100.14 | filing |
| 10 Aug 2026filed 11 Aug 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 10 Aug 2026filed 11 Aug 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $59K20,000 at $2.94 | filing |
| 10 Aug 2026filed 11 Aug 2026 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M11,683 at $98.51 | filing |
News
Critical Survey: Mirum Pharmaceuticals (NASDAQ:MIRM) versus United Therapeutics (NASDAQ:UTHR)MIRM · themarketsdaily.com · 25 Oct 2026Mirum Pharmaceuticals to report Livmarli trial results Monday (MIRM:NASDAQ)MIRM · seekingalpha.com · 12 Oct 2026
0 headlines in the last 90 days name Christopher Peetz; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.